FLG and Alzheimer disease: Meanwhile, when chemicals classified as therapeutic AHR-modulating agents (TAMAs) [95] act on AHR, the disease activity of AD is suppressed via increases in the levels of skin barrier proteins (such as FLG and LOR) and the induction of NRF2.